Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,142.3
3.5 (0.11%)

 

  • STI Straits Times Index
    3,142.3
    3.5 (0.11%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,514.0
    -0.6 (-0.04%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,086.4
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,381.2
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,775.8
    -194.5 (-0.70%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,097.0
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 145.9M
  • Value: 155.1M
  • Rise: 122
  • Fall: 51
  • Unch: 588

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.110+0.001
MM2 Asia0.071+0.004
Metal Component0.059+0.002
Olam Intl1.280-0.060
Leader Env0.080+0.002
GSS Energy0.068+0.001
KTL Global^0.119-0.003
Singtel2.250+0.020
Serial System0.146+0.010
Mercurius0.064+0.002

World Indices

World Indices
Name Last Change
Nasdaq 14,660.6 -180.1
HSI 25,086.4
HSCEI 8,879.6
Jakarta 6,097.0
Nikkei 225 27,753.9 -216.3
SSE Comp 3,381.2
Shanghai A 3,543.7
Shanghai B 256.9
KOSPI 3,241.8 +9.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ELI LILLY AND COMPANY ELI LILLY AND COMPANY
Updated on 27 Jul 2021 (End of trading day)
Last (USD): 243.580 Change: +0.370 High: 244.060 Remarks: -
Change (%): +0.15 Low: 242.660
Open 243.710 Yesterday's Close 243.21
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 2,116,536 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 6.45832 Trailing EPS (USD) e 6.35280 NAV (USD) b 7.1934
PE a 37.716 Trailing PE f 38.342 Price / NAV b 33.8616
Dividend (USD) d 2.952479 Cash In Hand (USD) g 3.1307 Issued & Paid-up Shares c 959,026,000
Dividend Yield (%) d 1.212 Price / Cash In Hand g 77.804 Treasury Shares h 463,000
Market Cap (M) 233,599.553 Enterprise Value (M) 246,953.253
Piotroski F Score 7 Exchange Code LLY Par Value ( $ ) n.a.
52 Weeks Volatility (%) 33.67 Free Float (%) 83.1
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 03 May 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 03 May 2021.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ELI LILLY AND COMPANY NYSE 233,599.553 37.716 38.342 33.8616 1.212
Industry Pharmaceuticals: Major NYSE 119,373.629 33.855 29.877 6.9631 2.734
Local Peer JOHNSON & JOHNSON NYSE 454,682.844 30.901 25.591 - 2.304
Local Peer PFIZER INC NYSE 235,662.749 24.507 21.248 3.4343 3.614
Local Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 222,311.234 27.378 24.717 4.1137 2.111
Local Peer ABBVIE INC NYSE 208,343.311 45.729 40.980 15.1965 4.101
Local Peer MERCK & CO INC NYSE 197,120.871 27.893 28.048 7.3157 3.183
Local Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 158,910.004 24.661 23.638 17.1905 1.501
Local Peer BRISTOL-MYERS SQUIBB CO NYSE 150,767.936 - - 4.0092 2.739
Local Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 99,425.997 13.486 14.644 4.8479 5.236
Local Peer TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS NYSE 52,938.865 14.932 14.932 1.1317 4.580
Local Peer BIOHAVEN PHARMACEUTICAL HLDG CO LTD NYSE 8,040.531 - - -29.1346 -
Local Peer ORGANON & CO NYSE 7,382.386 3.418 3.418 1.5634 -
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 3,360.347 11.014 8.676 2.2067 -
Other Local Peers ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), AMNEAL PHARMACEUTICALS INC (NYSE), LANNETT CO INC (NYSE)
Global Peer WUXI APPTEC HKEx 469,610.406 141.494 98.577 11.2186 0.221
Global Peer ROYALTY PHARMA PLC NASDAQ 23,798.790 24.408 24.464 4.8746 0.489
Global Peer HANSOH PHARMA HKEx 151,316.043 52.419 52.419 7.1395 0.302
Global Peer VIATRIS INC NASDAQ 16,812.461 - - 0.7851 -
Global Peer INNOVENT BIO HKEx 101,435.197 - - 9.7443 -
Global Peer CANSINOBIO-B HKEx 91,240.802 - - 12.6923 -
Global Peer CUREVAC NV NASDAQ 9,752.341 - - - -
Global Peer SINOPHARM HKEx 63,817.497 7.902 7.902 0.9550 4.105
Global Peer HUTCHMED HKEx 54,784.954 - - 16.4539 -
Global Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 6,299.398 - - 14.7083 -
Other Global Peers LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SH PHARMA (HKEx), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), REMEGEN-B (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CMS (HKEx), AKESO-B (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), INNOCARE-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CHINARES PHARMA (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), SIMCERE PHARMA (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), TRAD CHI MED (HKEx), NEKTAR THERAPEUTICS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CHINAGRANDPHARM (HKEx), IGM BIOSCIENCES INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), CSTONE PHARMA-B (HKEx), EVEREST MED-B (HKEx), HENLIUS (HKEx), ERASCA INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CARSGEN-B (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP (HKEx), HEPALINK (HKEx), OCUMENSION-B (HKEx), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), UNITED LAB (HKEx), ANTENGENE-B (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), Kimia Farma Tbk. (IDX), REPARE THERAPEUTICS INC (NASDAQ), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), GENERATION BIO CO (NASDAQ), IMMUNOTECH-B (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), PETIQ INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), SCICLONE PHARMA (HKEx), CKLIFE SCIENCES (HKEx), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), KEROS THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), SHINEWAY PHARM (HKEx), ANNEXON INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), EVOLUS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), TARSUS PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), Soho Global Health Tbk. (IDX), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), INOZYME PHARMA INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), IGBB (Bursa), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), RACE ONCOLOGY LTD (ASX), STARPHARMA HOLDINGS LIMITED (ASX), PROVENTION BIO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), XOMA CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), BIOMEA FUSION INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), ATHENEX INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), 89BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), THERATECHNOLOGIES INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), DURECT CORP (NASDAQ), BSTEAD (Bursa), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GAMIDA CELL LTD (NASDAQ), TOT BIOPHARM-B (HKEx), VERRICA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), VINCERX PHARMA INC (NASDAQ), PHARMA (Bursa), 180 LIFE SCIENCES CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), NEXIMMUNE INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), IMMUNIC INC (NASDAQ), MUSTANG BIO INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), IP (SET), ONCTERNAL THERAPEUTICS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CH BIOTECH SER (HKEx), PHASEBIO PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), POLYPID LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), ODONATE THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), RECCE PHARMACEUTICALS LTD (ASX), IX Biopharma (SGX), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), NOVAN INC (NASDAQ), ENTERA BIO LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GALECTO INC (NASDAQ), PROPHASE LABS INC (NASDAQ), CRESO PHARMA LTD (ASX), MEDIWOUND LTD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), MOLECULIN BIOTECH INC (NASDAQ), CHARMACY PHAR (HKEx), GRAYBUG VISION INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), Phapros Tbk. (IDX), DARE BIOSCIENCE INC (NASDAQ), PAK FAH YEOW (HKEx), NC HEALTHCARE (HKEx), Hyphens Pharma (SGX), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), BIOHLDG (Bursa), NOVA (Bursa), MODERN CHI MED (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), EXOPHARM LTD (ASX), SYNAPTOGENIX INC (NASDAQ), MANNATECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), INVION LTD (ASX), NEP INTERLONG (HKEx), ASSERTIO HOLDINGS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ACURX PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), VIRIOS THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), SANAI HEALTH GP (HKEx), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), PHARMAXIS (ASX), AVENUE THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TALI DIGITAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), ACRUX (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), ISLAND PHARMACEUTICALS LTD (ASX), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+8.560
+3.64 %
10 Days -+8.280
+3.52 %
20 Days -+14.210
+6.20 %
Medium Term Return 3 Months -+61.370
+33.68 %
6 Months 0.850+30.860
+14.91 %
1 Year 183.630+80.930
+162.66 %
Long Term Return 2 Years 186.400+134.890
+295.60 %
3 Years 188.815+144.770
+337.60 %
5 Years 193.040+160.260
+424.03 %
Annualised Return Annualised --
+39.27 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 129.210 - 245.280 Change From 1 Year Low +114.370 % Change From 1 Year Low (%) +88.51
Change From 1 Year High -1.700 % Change From 1 Year High (%) -0.69
2 Years Range 101.360 - 245.280 Change From 2 Years Low +142.220 % Change From 2 Years Low (%) +140.31
Change From 2 Years High -1.700 % Change From 2 Years High (%) -0.69
5 Years Range 64.180 - 245.280 Change From 5 Years Low +179.400 % Change From 5 Years Low (%) +279.53
Change From 5 Years High -1.700 % Change From 5 Years High (%) -0.69
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Historical Price Data

Date Open High Low Close Volume VWAP
26 Jul 2021 242.570 245.280 242.570 243.210 2,678,841 -
23 Jul 2021 239.280 244.550 238.560 244.150 2,447,745 -
22 Jul 2021 237.280 239.700 236.370 238.490 1,703,473 -
21 Jul 2021 236.380 237.370 233.590 237.290 1,651,460 -
20 Jul 2021 235.000 237.750 233.935 235.020 2,297,806 -
19 Jul 2021 231.880 234.300 230.570 234.140 2,305,304 -
16 Jul 2021 232.500 233.040 231.210 232.460 2,229,046 -
15 Jul 2021 235.010 235.990 230.690 231.470 3,611,114 -
14 Jul 2021 235.790 237.230 234.730 236.350 2,102,611 -
13 Jul 2021 235.980 236.650 234.030 235.300 1,974,039 -
12 Jul 2021 235.170 238.000 235.150 236.010 2,928,592 -
09 Jul 2021 237.170 238.472 232.750 234.990 4,030,051 -
08 Jul 2021 233.830 237.270 232.100 237.120 2,430,792 -
07 Jul 2021 234.680 236.590 233.460 235.820 3,141,497 -
06 Jul 2021 233.630 235.575 233.230 235.420 3,125,201 -
02 Jul 2021 231.970 234.210 231.330 233.960 1,994,038 -
01 Jul 2021 229.510 231.500 228.660 231.130 1,977,297 -
30 Jun 2021 230.090 230.846 229.060 229.520 1,786,094 -
29 Jun 2021 228.250 231.400 227.850 229.370 1,620,032 -
28 Jun 2021 229.000 229.880 226.878 228.220 2,507,467 -
25 Jun 2021 233.120 233.490 229.390 230.220 6,991,473 -
24 Jun 2021 234.920 239.370 230.420 232.970 12,286,040 -
Summary
Current 2 Weeks
(13 Jul 2021 to 26 Jul 2021)
235.980 245.280 230.570 243.210 23,001,439 -
Previous 2 Weeks
(28 Jun 2021 to 12 Jul 2021)
229.000 245.280 226.878 236.010 25,541,061 -
4 Weeks from
(28 May 2021 to 25 Jun 2021)
199.120 245.280 198.530 230.220 91,710,651 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.